Click to copy, then share by pasting into your messages, comments, social media posts and websites.
Click to copy, then add into your webpages so users can view and engage with this video from your site.
We also accept reports via email. Please see the Guidelines Enforcement Process for instructions on how to make a request via email.
Thank you for submitting your report
We will investigate and take the appropriate action.
FDA Advisory Committee - COVID product Concerns by Dr. Jessica Rose 9/17/2021
The U.S. Food and Drug Administration (FDA) held a virtual meeting titled Vaccines and Related Biological Products Advisory Committee on Friday, September 17th.
“Join us for a Vaccines and Related Biological Products Advisory Committee meeting to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older.”
This was an eight-hour virtual meeting. This video clip is a short 2.5 minute speech given by Dr. Jessica Rose during the meeting.
“My name is Dr. Jessica Rose, and I’m a viral immunologist and computational biologist. This is a bar plot that shows the past ten years of VAERS data plotted against the total number of adverse event reports for all vaccines for the year 2011 through 2020 and for COVID-associated products only for 2021.
The left box represents all adverse event reports. And the right-hand column represents all deaths adverse event reports. There’s an over 1000% increase in the total number of adverse events for 2021 and we are not done with 2021. This is highly anomalous on both fronts.
These increased reporting rates are not due to increased rates in injections and not due to simulated reporting. This has been shown using a comparative analysis of influenza data.
The onus is on the public health officials, the FDA, the CDC, and policymakers to answer to these anomalies and acknowledge the clear risk signals emerging from VAERS data, and to confront the issue of COVID injectable products huge risks that, in my opinion, outweigh any potential benefits associated with these products, especially for children.
This is a time series plot that shows the total cumulative number of cardiovascular, immunological, and neurological adverse events for 2021 associated with COVID products. For the cumulative absolute counts are normalized for the total number of fully injected individuals in the U.S. we can see that one and 660 individuals are succumbing to and reporting immunological adverse events associated with the COVID product. The underreporting factor is not considered here.
This is a phylogenetic tree showing the emergence of the Alpha against Delta variants of COVID-19, COVID-19 over time. The emergence of both of these variants and their subsequent clustering arose in very close temporal proximity to the rollout of the COVID product in Israel. Israel is one of the most injected countries, and it appears from this data that this represents a clear failure of these products to provide protective immunity against emergent variants and to prevent transmission, regardless of how many additional shots administered. And this begs the question as to whether these injection rollouts are driving the emergence of the new variants.
There’s a clear and present danger of the emergence of variants of concern if we continue with these alleged booster shots. Thank you.
Full length FDA video link on YouTube: "Vaccines and Related Biological Products Advisory Committee – 9/17/2021" Dr. Jessica Rose's speech starts at this link: https://youtu.be/WFph7-6t34M?t=14989
|Sensitivity||Normal - Content that is suitable for ages 16 and over|
1 year, 4 months ago
Warning - This video exceeds your sensitivity preference!
To dismiss this warning and continue to watch the video please click on the button below.
Note - Autoplay has been disabled for this video.
This advertisement has been selected by the video's creator, Bobbie-D.
This advertisement has been selected by BitChute. Displaying these adverts helps support the growth and sustainability of the platform.
This advertisement has been sourced through third party advertising partners on behalf of BitChute. Displaying these adverts helps support the growth and sustainability of the platform.